Alaunos' ALN1003 Preclinical Data Shows Significant Liver Weight Reduction in Obesity Model
TCRT sits 41% above its 52-week low of $1.67.
Summary
Alaunos Therapeutics announced new preclinical data for its obesity drug candidate, ALN1003, showing lower liver weight after adjusting for body fat percentage in a 48-day mouse study. This finding provides additional supportive evidence for ALN1003's potential liver-related effects, consistent with prior positive data on liver markers and insulin resistance. The news follows an 8-K filed minutes earlier today, detailing the 'additional evidence' mentioned. While positive for the drug's profile, the company faces severe financial distress, with cash sufficient only into Q2 2026 and ongoing Nasdaq non-compliance.
At the time of this announcement, TCRT was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $1.67 to $6.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.